Wednesday, April 27, 2016

Facebook (FB) Reports 1Q'16 Results (And They Were Good)

Facebook (FB) reported 1Q'16 results today (02016.04.27) after the market closed. After hours trading is hinting that FB could hit a new all-time high tomorrow.

From Facebook's press release...

Capital expenditures for the first quarter of 2016 were $1.13 billion.

Cash and cash equivalents and marketable securities were $20.62 billion at the end of the first quarter of 2016.

Free cash flow for the first quarter of 2016 was $1.85 billion.

Effective tax rate was 27%.

CEO Mark Zuckerburg... "We had a great start to the year. "We're focused on our 10 year roadmap to give everyone in the world the power to share anything they want with anyone."

FB closed today (02016.04.27) at $108.76. 52-week range: $72.00 - $117.59.

iRobot (IRBT) Hits New 52-Week on 1Q'16 Results

iRobot (IRBT) spiked to a new 52-week high of $38.08 today (02016.04.27) after reporting 1Q'16 results.
"Our first quarter results were outstanding. Home Robot revenue grew 15% over Q1 2015, driven by significant growth in the United States following a record Q4 2015," said Colin Angle, chairman and chief executive officer of iRobot.

At $38.02, iRobot has an approximate market value of $1.1 billion, which seems low to me. The PSR (Price-Sales-Ratio) is less than 2.0 and this also seems low to me. I'll sell some IRBT at $50.27 (i.e. 16 $Pi).

Friday, April 22, 2016

Alphabet (GOOG/GOOGL) Reports 1Q'16 Results

Alphabet (GOOG/GOOGL) reported 1Q'02016 results when the market closed yesterday (02016.04.21).

I've be recording Google's (now Alphabet's) quarterly results since 4th-quarter 02008. Google reported 1Q'02016 results yesterday. In a nutshell: For the first 91 days of 02016, Alphabet generated $5.23 billion free cash flow while hiring 2,301 new workers and spending $2.428 billion on capital expenditures and paying an effective tax rate of 18%. Alphabet ended March with $75.264 billion in "cash." Seems like a decent quarter to me, yet right now (02016.04.22 at 7:42am MST) Alphabet has lost 5+% of its market price.

Tuesday, April 19, 2016

Illumina (ILMN) -- Heading For a New 52-Week Low?

Illumina (ILMN) lost 20+% of its market value when the market opened today (02016.04.19) after the company announced preliminary Q1'16 results that failed to match or exceed expectations. ILMN was at $139.09 at :40am EDT on 02016.04.19. 52-week range: $130.00 - $242.37. In other words, ILMN is approaching a new 52-week low. Hmm... Maybe we're nearing the end of the Genomics Age.

Friday, April 15, 2016

Red Hat (RHT) Gets an Upgrade by Some Investment Firm

Red Hat (RHT) was upgraded to "overweight" from "sector weight" at Pacific Crest (target price: $88). The GDT::Portfolio's target price is $101.22. RHT closed yesterday (02016.04.14) at $74.45. 52-week range: $59.59 - $84.44.

Finance.Yahoo.com: "Red Hat, Inc. provides open source software solutions to enterprise customers worldwide. It develops and offers operating system, virtualization, middleware, storage, and cloud technologies."

Adamis Pharmaceuticals (ADMP) Hits New 52-Week High

Adamis Pharmaceuticals (ADMP) spiked to a new 52-week high of $8.12 before closing yesterday (02016.04.14) at $8.07. Three months ago, on 02016.01.20, ADMP hit an intra-day low of $3.63. Yesterday's volume was 419,290 vs. 64,592. [There are ~13.46 million ADMP shares.] The GDT::Portfolio average cost per ADMP is $6.23, so at least our investment is currently above water.

Adamis is "focused on developing and commercializing products in the therapeutic areas of allergy and respiratory disease."

Monday, April 4, 2016

Keryx Biopharmaceuticals (KERX) Added to GDT::Portfolio

Keryx Biopharmaceuticals (KERX) was added to the GDT::Portfolio on 02016.04.01 (yes, April Fools' Day). We paid $4.55 per KERX share. " Keryx Biopharmaceuticals focuses on providing therapies for patients with renal disease in the United States."

Steven C. Gilman joined the Keryx board on 02016.03.31. Gilman is also on the board of Vericel (VCEL) and VCEL is a GDT::Portfolio stock.